C9113 — Injection, pantoprazole sodium, per vial
C9113 is a HCPCS Level II code for injection, pantoprazole sodium, per vial. It belongs to the Outpatient Prospective Payment System section. It was terminated on June 30, 2024 and is not valid on new claims.
This code has been terminated
CMS terminated C9113 on June 30, 2024. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Special coverage instructions apply
There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for C9113
- Long descriptor
- Injection, pantoprazole sodium, per vial
- Short descriptor
- Inj pantoprazole sodium, via
- Added
- January 1, 2002
- Terminated
- June 30, 2024
- BETOS
- O1E
- Pricing indicator
- 53 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Statute.
Codes adjacent to C9113
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If C9113 is not quite right, the correct code is very often within a few positions of it.
- C9092Injection, triamcinolone acetonide, suprachoroidal (xipere), 1 mgterminated
- C9093Injection, ranibizumab, via sustained release intravitreal implant (susvimo), 0.1 mgterminated
- C9094Inj, sutimlimab-jome, 10 mgterminated
- C9095Inj, tebentafusp-tebn, 1 mcgterminated
- C9096Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgramterminated
- C9097Inj, faricimab-svoa, 0.1 mgterminated
- C9098Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic doseterminated
- C9101Injection, oliceridine, 0.1 mg
- C9121Injection, argatroban, per 5 mgterminated
- C9122Mometasone furoate sinus implant, 10 micrograms (sinuva)terminated
- C9132Prothrombin complex concentrate (human), kcentra, per i.u. of factor ix activityterminated
- C9133Factor ix (antihemophilic factor, recombinant), rixubis, per i.u.terminated
- C9134Factor xiii (antihemophilic factor, recombinant), tretten, per 10 i.u.terminated
- C9135Factor ix (antihemophilic factor, recombinant), alprolix, per i.u.terminated
- C9136Injection, factor viii, fc fusion protein, (recombinant), per i.u.terminated
- C9137Injection, factor viii (antihemophilic factor, recombinant) pegylated, 1 i.u.terminated
Questions about C9113
What is HCPCS code C9113?
C9113 is a HCPCS Level II code for injection, pantoprazole sodium, per vial. It sits in the Outpatient Prospective Payment System section.
Does Medicare cover C9113?
The CMS HCPCS file marks C9113 as "Special coverage instructions apply". There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
Is C9113 still valid?
No. C9113 was terminated on June 30, 2024 and should not be used on new claims.